Skip to content Skip to footer

VIEWPOINTS

Viewpoints_Xochitl Javier
Redefining Technology: Xochitl Javier from Thermo Fisher Scientific in Conversation with PharmaShots
Shots:  Raman Analyzers are widely used in the biopharma industry to analyze different substances. Based on the principles of Raman Spectroscopy, Raman Analyzers provide information about their chemical composition and structure when interacting with laser  Today, at PharmaShots, we have Xochitl Javier, Director, Product Management & Marketing, Thermo Fisher Scientific, shedding light on the TruScan…
Viewpoints_Andrew Menzies-Gow
AstraZeneca at ATS’24: Andrew Menzies-Gow from AstraZeneca in a Stimulating Conversation with PharmaShots
Shots:  AstraZeneca presented 59 abstracts, including 12 late-breaking posters at the American Thoracic Society, focussing on the unmet needs in COPD, EGPA, and other chronic respiratory diseases  Today, at PharmaShots, we have Andrew Menzies-Gow, sharing insights from the MANDARA study that evaluated Fasenra (benralizumab) for EGPA, a rare debilitating condition  Andrew stresses reducing the use…
Viewpoints_Jesse Mendelsohn
Drug Pricing & Rebate Management: Jesse Mendelsohn from Model N in Dialogue Exchange with PharmaShots
Shots:  Drug pricing reforms from the IRA continue to impact pharmaceutical companies. The rebates ensued from the IRA guidelines are heavily affecting the revenues of biopharma companies  Today, at PharmaShots we have Jesse Mendelsohn, Sr. Vice President at Model N shedding light on the company’s recently launched solution called Medicare Part D inflation rebate-per-unit  With…
VIEWPOINTS_Roy Maute_2024
Macrophage Checkpoint Therapy: Roy Maute from Pheast Therapeutics in a Riveting Conversation with PharmaShots
Shots:  Recently Pheast Therapeutics shared the preclinical data for PHST001, an anti-CD24 macrophage checkpoint inhibitor at the 20th Annual PEGS Boston Summit  Today, at PharmaShots, we had a dialogue exchange with Roy Maute, Cofounder and CEO of Pheast Therapeutics  Pheast Therapeutics currently plans to initiate a clinical trial in H1’25  Saurabh: Can you walk me…
VIEWPOINTS_Moitreyee Chatterjee-Kishore1_Kohei Shitara2_2024
Unlocking Approval: Moitreyee Chatterjee-Kishore from Astellas & Kohei Shitara in Conversation with PharmaShots
Shots:  East Asia and East Europe report significant incidences of Gastric Cancer. In 2022, Japan registered around 44,000 mortalities due to Gastric Cancer  VYLOY, an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, received Japan’s approval in combination with chemotherapy for patients with HER2 -ve, CLDN18.2+ve, unresectable, advanced, or recurrent gastric cancer  Today, at PharmaShots we have Moitreyee…
VIEWPOINTS_Kari Wong1_Emma Tallantyre2_2024
Enhancing Multiple Sclerosis Research: Dr. Kari Wong and Dr. Emma Tallantyre in Conversation with PharmaShots
Shots:  Multiple Sclerosis affects over 2.8M people globally. Despite several tech infusions in MS research, the exact cause of the condition remains unknown  Recently, Metabolon, known for providing metabolomics solutions joined hands with the Division of Psychological Medicine and Clinical Neuroscience (DPMCN) at Cardiff University to discover new biomarkers to expedite the understanding and treatment…
VIEWPOINTS_Donna Carstens_2024
SEA Management: Donna Carstens from AstraZeneca in a Riveting Conversation with PharmaShots
Shots:  Recently AstraZeneca’s FASENRA (benralizumab) received approval from the US FDA as an add-on maintenance treatment for patients (≥ 6 yrs.) with severe asthma and with an eosinophilic phenotype  Today, at PharmaShots we have with us Donna Carstens, Senior Medical Director Respiratory, Fasenra at AstraZeneca  Donna shares insights from the TATE study an open-label, multinational,…